Irbesartan in the regression of left ventricular hypertrophy

被引：0
|
作者：
Malmqvist, K [1 ]
Kahan, T [1 ]
Edner, M [1 ]
Held, C [1 ]
Osbakken, M [1 ]
机构：
[1] Karolinska Inst, Danderyd Hosp, Div Internal Med, S-18288 Danderyd, Sweden
来源：
XIII WORLD CONGRESS OF CARDIOLOGY: FREE PAPERS | 1998年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Left ventricular hypertrophy (LVH) is a major independent risk factor for cardiovascular disease and a significant independent predictor of mortality (Sullivan et ai, 1993). The effects of irbesartan (IRBE) on the regression of left ventricular hypertrophy (LVH) were compared to those of atenolol (ATN) in a double-blind, 48-week study. Despite similar reductions in blood pressure (BP), LVH regressed sooner and to a greater degree with IRBE compared with ATN. Thus, IRBE produced superior end organ protection with better tolerability.
引用
收藏
页码：427 / 431
页数：5
相关论文
共 50 条
  • [31] Left ventricular longitudinal function in hypertensive patients with left ventricular hypertrophy regression
    Pavlioukova, E. N.
    Bahmetieva, T. A.
    Karpov, R. S.
    JOURNAL OF HYPERTENSION, 2006, 24 : S55 - S55
  • [32] Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy
    Gaudio, C
    Ferri, FM
    Giovannini, M
    Pannarale, G
    Puddu, PE
    Vittore, A
    Fera, MS
    Vizza, CD
    Fedele, F
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (05) : 622 - 628
  • [33] Left ventricular longitudinal function in hypertensive patients with left ventricular hypertrophy regression
    Pavlyukova, E.
    EUROPEAN HEART JOURNAL, 2006, 27 : 982 - 982
  • [34] Change of Monocyte Phenotype in Hypertensive Patients with Left Ventricular Hypertrophy and Intervention of Irbesartan
    Yang, Lina
    Ding, Yanchun
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (16) : C151 - C152
  • [35] Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass:: the LIFE study
    Okin, PM
    Devereux, RB
    Liu, JE
    Oikarinen, L
    Jern, S
    Kjeldsen, SE
    Julius, S
    Wachtell, K
    Nieminen, MS
    Dahlöf, B
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) : 403 - 409
  • [36] Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study
    P M Okin
    R B Devereux
    J E Liu
    L Oikarinen
    S Jern
    S E Kjeldsen
    S Julius
    K Wachtell
    M S Nieminen
    B Dahlöf
    Journal of Human Hypertension, 2004, 18 : 403 - 409
  • [37] Different actions of irbesartan and atenolol on cardiac repolarisation in hypertensive left ventricular hypertrophy
    Malmqvist, K
    Kahan, T
    Edner, M
    Bergfeldt, L
    Kahan, T
    Edner, M
    Bergfeldt, L
    EUROPEAN HEART JOURNAL, 2002, 23 : 670 - 670
  • [38] Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension
    Degirmenci, H.
    Acikel, M.
    Bakirci, E. M.
    Duman, H.
    Demirelli, S.
    Tas, H.
    Simsek, Z.
    Karakelleoglu, S.
    Aksakal, E.
    Erol, M. K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (05) : 630 - 637
  • [39] Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy
    Müller-Brunotte, R
    Edner, M
    Malmqvist, K
    Kahan, T
    JOURNAL OF HYPERTENSION, 2005, 23 (03) : 633 - 640
  • [40] Change in electrocardiographic left ventricular hypertrophy criteria predict regression of anatomic left ventricular hypertrophy: The LIFE study
    Okin, PM
    Liu, JE
    Jem, S
    Julius, S
    Kjeldsen, SE
    Wachtell, K
    Dahlof, B
    CIRCULATION, 1999, 100 (18) : 536 - 536
12345